Background
==========

Many papers have clearly demonstrated that HIV-1 RNA plasma viral load quantitative determination is a pivotal parameter to monitor viral replication and the effectiveness of HAART therapy \[[@B1]-[@B5]\]. In addition, a growing number of observations showed that measurement of HIV-1 DNA proviral load could provide crucial information on the reservoir and dynamics of HIV-1 infection \[[@B5],[@B6]\] since the persistence of HIV-DNA in peripheral blood mononuclear cells (PBMC) and lymph nodes is a major drawback to eradication of infection \[[@B7],[@B8]\]. Quantitative analysis of proviral DNA in HAART-treated patients showed opposite results: on one hand, the decline in DNA load seemed to indicate the long term impact and effectiveness of retroviral treatment \[[@B9]-[@B12]\], on the other DNA levels remained stable over several years in PI ART naïve patients \[[@B2],[@B13]\].

Recent studies also indicate that viral replication persists even in individuals with prolonged suppression of plasma HIV-1 RNA levels to fewer than 50 copies/ml \[[@B5],[@B8],[@B14]-[@B16]\], confirming that \"undetectable viremia\" cannot be considered evidence of complete viral replication suppression. The findings of a slow and/or incomplete decay imply that current HAART regimens do not completely suppress viral replication. However the decreasing morbidity and mortality in HAART-treated HIV-1 seropositive patients and the following restoration, preservation of immunologic function and improvement in quality of life demand the ongoing use of these drugs. The new therapeutic challenge is to find new immunological or pharmacological approaches aimed at purging HIV-1 DNA proviral reservoirs \[[@B19]\]. Several recent studies have addressed structured treatment interruption (STI), as conceivable strategy to stimulate and enhance the immune system HIV-1 specific response to tackle viral replication in the absence of chemotherapy \[[@B17]-[@B19]\] even though several reports showed that only 10--20% of chronically infected patients achieved a short-term suppression of viral replication \[[@B20]-[@B22]\].

Since a growing number of studies involving quantification of cellular HIV-1 DNA acknowledge the importance of accurate quantification of proviral DNA in peripheral blood cells for monitoring diseases progression, we selected a small but peculiar group of patients, who decided to interrupt antiretroviral therapy, irrespective of current guidelines \[[@B23]\] and despite virologic failure. In particular, sequential blood samples of 10 patients under antiretroviral treatment from 1997 with two NRTIs, who refused to continue any antiviral regimen, were analyzed for 16 -- 24 weeks to study the possible relationship between DNA and RNA viral load.

Methods
=======

Patients
--------

Ten HIV-1 infected adults under antiretroviral treatment since 1997 with two NRTIs (stavudine \[D4T\] and lamivudine \[3TC\] or zidovudine \[AZT\] and lamivudine \[3TC\] or zidovudine \[AZT\] and zalcitabina \[DDC\] or zidovudine \[AZT\] and didanosine \[DDI\]) were selected for this study. All these patients refused to continue any antiviral regimen despite an assessed virologic failure (HIV-1 RNA viral load \> 50 copies/ml) and were followed-up monthly for a variable period ranging from 16 to 24 weeks up to the moment in which they agreed to begin a new therapeutic protocol. Sequential blood samples were obtained at baseline (time 0: voluntary therapy interruption) and every four weeks (time 1-time 7) and analyzed for viral load (RNA and DNA), and CD4 levels. The baseline characteristics of the patients included in the study are shown in Table [1](#T1){ref-type="table"}. All the subjects were enrolled after informed consent according the Helsinki declaration of 1975.

###### 

Baseline characteristics of HIV infected patients enrolled in the study at time of therapy suspension.

  *Characteristic*                        
  --------------------------------------- ------------------------
  Gender                                  7 males, 3 females
  Heterosexual                            8
  IVDUs                                   2
  Age (mean years ± SD)                   36.27 ± 8.32
  CD4 count cells × 10^6^per l (median)   548.45 ± 63 cells/mmc.
  Plasma HIV-1 RNA copies/ml (median)     3.7 × 10^3^

HIV-1 RNA quantification
------------------------

All the whole blood samples were centrifuged at 2500 rpm for 20 min and plasma was stored at -80°C until use. Plasma was analyzed for HIV-1 RNA viral using the Quantiplex HIV-RNA-3.0 assay (Chiron Corporation, Emeryville, CA, USA), according to the manufacturer\'s instructions. The amount of HIV RNA levels was expressed as copy number per ml of plasma and the lowest detection limit of the assay was 50 copies/ml.

DNA extraction and purification of PBMCs for HIV-1 DNA quantification
---------------------------------------------------------------------

Peripheral blood mononuclear cells (PBMC) were isolated from whole blood by Ficoll-Paque gradient separation (Amersham Pharmacia). Cell pellets, corresponding to 5 × 10^6^PBMC were prepared and stored at -80°C. DNA was extracted and purified from each PBMC pellet by DNAeasy tissue kit (Qiagen) following the manufacturers\' instructions. The pGEMBH10 HIV plasmid \[[@B8],[@B14]\] was purified by Midi plasmid extraction kit (Qiagen, Hilden, Germany) following the manufacturers\' instructions. Plasmid and cellular DNA concentration and purity were determined by spectrophotometric analysis at 260/280 nm.

Determination of HIV-1 proviral DNA by SYBR green real-time PCR
---------------------------------------------------------------

SYBR green real-time PCR assay was performed, as previously described \[[@B8],[@B14]\] in 20 μl PCR mixture volume consisting in 2× Quantitect SYBR Green PCR Master Mix (Qiagen) containing HotStarTaq DNA polymerase, 200 nM of each oligonucleotide primer (SK431, SK462) \[[@B24]\] and 600 ng of DNA extracted from clinical samples (approximately the DNA content of 200.000 cells) or scalar dilution of pGEMBH10 HIV plasmid (from 10^5^to 10 copies). Initial activation of HotStar Taq DNA Polymerase at 95°C for 15 min; 45 cycles in four steps: 94°C for 10 s, 60°C for 30 s, 72°C for 30 s, 78°C for 3 s. At the end of amplification cycles, melting temperature analysis was carried out by a slow increase in temperature (0.1°C/s) up to 94°C. Amplification, data acquisition and analysis were carried out by a LightCycler instrument (Roche, Mannheim, Germany) using LightCycler 5.3.2 software (Roche). This software, coupled with the LightCycler instrument, determines the threshold cycle (Ct) representing the number of cycles in which the fluorescence intensity is significantly above the background fluorescence. Ct is directly proportional to log~10~of the copy number of the input templates with respect to a standard curve generated in parallel. SYBR green molecules bind all double stranded DNA molecules emitting a fluorescent signal, on binding, proportional to the amplicon synthesis during the PCR reaction. This property elicited an accurate analysis of the melting temperature curve of the amplified fragments generated by real-time PCR to determine the detection and quantitation of specific products. Thus the single analysis of fluorescence was performed at 75°C by LightCycler 5.3.2 software in each cycle to rule out any non-specific interference (i.e. dimer primer). All samples from patients were run in duplicate and were also analyzed by SYBR Green real-time PCR for globin gene in a parallel run to check the equal amount in all samples determined by spectrophotometric data as described.

Statistical analysis
--------------------

Statistical analysis was carried out using Student\'s *t*-test or Mann-Whitney test. Correlation was determined by Spearman\'s rank correlation.

Results
=======

Longitudinal analysis of RNA plasma viral load detection by b-DNA assay
-----------------------------------------------------------------------

As expected, therapy interruption determined a significant increase in RNA viral load in all HIV-1 seropositive patients enrolled in the study. In particular, all patients\' plasma showed a significant (Mann-Whitney test p = 0.036) increase in viral load already one month after therapy interruption (time 1) showing a median value of 1.7 × 10^4^(4.2 log~10~) in comparison to 3.7 × 10^3^copies/ml (3.5 log~10~) observed at median baseline value (time 0). Moreover, plasma viral load reached higher levels \[median value of 1,1 × 10^5^HIV-1RNA copies/ml (5 log~10~)\] at the end of observation period (p = 0.014) (Table [2](#T2){ref-type="table"}). Hence, we assessed an increase in viral replication ranging from 0.5 log~10~to more than 1 log~10~at the end of observation period (p = 0.00).

###### 

Longitudinal values of HIV RNA and DNA viral load, CD4 levels in patients on long term treatment with two NRTIs from therapy suspension (time 0) onwards.

             RNA Viral Load (copies/ml)   DNA Viral Load (copies/10^6^PMBCs)   CD4 cell count (x10^6^cells/L)              RNA Viral Load (copies/ml)   DNA Viral Load (copies/10^6^PMBCs)   CD4 cell count (x10^6^cells/L)
  ---------- ---------------------------- ------------------------------------ -------------------------------- ---------- ---------------------------- ------------------------------------ --------------------------------
  **Pt 1**                                                                                                      **Pt6**                                                                      
  Time0      6300                                                              335                              Time0      2940                                                              625
  Time1      20800                        1600                                 324                              Time1      2500                         1100                                 625
  Time2      30000                        2200                                 324                              Time2      16000                        1400                                 529
  Time3      58000                        1800                                 340                              Time3      7800                         630                                  625
  Time4      100000                       2000                                 300                              Time4      25000                        620                                  552
  Time5      120000                       3800                                 220                              Time5      24000                        730                                  750
                                                                                                                                                                                             
  **Pt2**                                                                                                       Time6      17000                        890                                  483
                                                                                                                                                                                             
  Time0      11000                                                             345                              **Pt 7**                                                                     
  Time1      22000                        1200                                 345                              Time0      1600                                                              462
  Time2      70000                        1900                                 365                              Time1      6800                         920                                  450
  Time3      100000                       1500                                 256                              Time2      1700                         750                                  456
  Time4      150000                       1000                                 304                              Time3      4400                         910                                  384
  Time5      148000                       770                                  240                              Time4      4000                         690                                  380
  Time6      170000                       990                                  238                              Time5      2700                         400                                  399
                                                                                                                                                                                             
  **Pt3**                                                                                                       Time6      2800                         300                                  342
                                                                                                                                                                                             
  Time0      3600                                                              551                              Pt8                                                                          
  Time1      43000                        2300                                 448                              Time0      3970                                                              616
  Time2      58100                        820                                  266                              Time1      4000                         1000                                 616
  Time3      49000                        580                                  560                              Time2      85000                        660                                  532
  Time4      58000                        990                                  360                              Time3      100000                       490                                  361
                                                                                                                                                                                             
  **Pt4**                                                                                                       Time4      84000                        230                                  420
  Time0      1220                                                              572                              Time5      74000                        330                                  456
  Time1      1400                         1300                                 570                              Time6      100000                       550                                  460
                                                                                                                                                                                             
  Time2      24000                        1890                                 522                              Pt9                                                                          
  Time3      46000                        960                                  572                              Time0      10500                                                             680
  Time4      27000                        500                                  576                              Time1      14000                        1500                                 624
  Time5      32000                        700                                  432                              Time2      16000                        1000                                 480
  Time6      31000                        550                                  348                              Time3      39000                        450                                  588
                                                                                                                                                                                             
  **Pt5**                                                                                                       Time4      33000                        1100                                 520
  Time0      4900                                                              494                              Time5      145000                       3100                                 390
                                                                                                                                                                                             
  Time1      93000                        1500                                 528                              Pt10                                                                         
  Time2      100000                       1050                                 483                              Time0      1130                                                              578
  Time3      150000                       830                                  460                              Time1      69000                        612                                  420
  Time4      250000                       1000                                 404                              Time2      66000                        1200                                 320
                                                                                                                Time3      100000                       1600                                 350
                                                                                                                Time4      210000                       2800                                 267

Longitudinal analysis of PBMC DNA proviral load detection by quantitative real time PCR assay
---------------------------------------------------------------------------------------------

In parallel experiments, we quantified proviral DNA load in PBMC isolated from patients\' whole blood sequential samples at fixed times after therapy suspension. The median number of samples available for each patient was five \[1 month after the therapy suspension (time 1) and then each month up to the end of observation period\], ranging from two to seven. The median follow-up was 5.5 (4--7) months.

The majority of patients showed a fluctuating trend in DNA viral load. Three patients (N°1, N°9 and 10) showed an increase in DNA viral load detectable from the first through to the last available sample. Even though DNA amount reached a significantly (considered as a variation of 0.5 -- 1 log~10~) higher value only in samples from patients N°1 and N°10 (from 3.2 log~10~to 3.7 log~10~and from 2.7 log~10~to 3.4 log~10~respectively), sequential PBMC samples obtained from patient N°9 exhibited a clear tendency to increase (and from 3.1 log~10~to 3.5 log~10~copy of HIV-1 DNA per 10^6^PBMCs respectively) redoubling the DNA content. Moreover, most of the other samples obtained from patients N°2, N°3, N°4, N°5 and N°6 showed a swinging course. After an apparent decline in proviral DNA content during the follow-up, in the latest samples a moderate increase in proviral DNA load was observed in PBMC from all patients. In contrast, a decrease of HIV-1 proviral DNA content was noticed from a baseline value of 1.3 × 10^3^copies per ml (3.1 log~10~) to 5.5 × 10^2^HIV-1 DNA copies per ml (2.7 log~10~) and from 9.2 × 10^2^(2.9 log~10~) to 3.0 × 10^2^(2.4 log~10~) in patients N°4 and 7 only.

As expected, a statistical analysis of PBMCs HIV proviral DNA content and plasma RNA viral load of all 10 patients failed to disclose any significant correlation between HIV-1 proviral DNA load and HIV-1 RNA viral load (Mann-Wittney test) confirming our previous data \[[@B14]\].

CD4 cell count determination
----------------------------

All the patients enrolled in the study showed a CD4 reduction during the follow-up. All patients, except two (Patients N°1 and N°2), interrupted therapy with a level of CD4 cells \>400 cells/mmc and, as expected, showed a sharp \[(N°1 and N°3 (34% reduction), N°2 (31% reduction), N°4 (39%), N°9 (42%), N°10 (53%)\] decrease or a moderate decline \[N°5 (18% reduction), N°6 (22% reduction) N°7 and 8 (25% reduction)\] at the end of our observation period. No correlation was found (r = 0.5, p \> 0.005) between the course of DNA viral load and CD4 levels, but high RNA levels were significantly associated with lower CD4 counts, demonstrating a significant inverse correlation between CD4+ cell counts and HIV-1 RNA levels (p = 0.001).

Discussion
==========

During recent years, planned therapy interruption has been entertained in specific clinical situations even though the potential role of this choice with respect to the balance between risk of disease progression and potential benefits remains to be elucidated. Our study focused on a peculiar group of patients who voluntary opted to suspend antiretroviral therapy for a variable period of time, ranging from five to seven months, despite of virologic failure. Our follow-up ceased when patients agreed to a new therapeutic protocol.

Our study aimed to evaluate the virologic evolution of these subjects focusing on DNA proviral load course, since accurate quantification of HIV-1 DNA in peripheral blood cells is an important parameter for monitoring disease progression and predicting the clinical outcome of infection \[[@B3],[@B27]-[@B29]\]. Several studies, mostly addressed to patients under different therapy protocols, have shown that the evaluation of DNA content may have important implications for understanding the virological response to combination therapy \[[@B25],[@B26]\]. Even thought the plasma HIV-1 RNA load is widely considered a direct indicator of viral replication in infected individuals, the formation, stability and turnover of potentially infectious virus in the HIV-1 DNA proviral pool has important indication for the understanding of HIV pathogenesis \[[@B5],[@B6],[@B11]\]. Moreover, Vitone *et al*. \[[@B8]\] recently demonstrated that the decrease in HIV-1 DNA proviral load is inversely correlated to CD4 level in HIV-1 seropositive patients with a persistently undetectable viremia (HIV-1 RNA viral load).

Current data on course of DNA viral load during infection are inconclusive \[[@B1]-[@B9]\], but most studies suggest that HIV-1 DNA proviral quantification is useful to monitor the decay of the HIV reservoir towards disease remission, distinguishing \"responder\" from \"non responder\" patients \[[@B3],[@B28]\].

Our results, obtained from patients, therapy-free during the virolgical follow-up, showed a viral rebound, one month after therapy suspension, assessed by plasma RNA values in all patients. The analysis of HIV-1 DNA proviral content displayed a clear increase from the baseline value in three patients, confirming that an active viral replication results in elevated viremia (HIV-1 RNA load) and in an increased number of cells containing viral DNA \[[@B27],[@B28]\]. Also, patients who showed an apparent decrease in DNA copy number during the first step of our follow-up, came to present a rebound of DNA in PBMCs at the end of observation period. These observations might suggest that previous therapy controlled the amount of viral DNA only for a limited period of time and a likely viral rebound, as assessed by an increase in DNA amount, was observed only some months later.

Finally, in contrast with other patients, two subjects showed a clear HIV-1 DNA proviral decrease over time, in the absence of therapy and a steady HIV-1 RNA viral load detectable in plasma samples. In both cases a HIV-1 DNA proviral decline due to a long lasting effect of therapy could be ruled out, since both patients showed high levels of viral replication by increasing value of HIV-1 RNA viral load over time. In an attempt to explain the course of HIV-1 DNA proviral in these subjects, we had to take into consideration that our assay, a SYBR green based real time PCR measures both integrated and unintegrated HIV-1 DNA form on PBMCs. There is evidence that only a fraction of integrated and unintegrated HIV-1 DNA is replication competent \[[@B25]\]. Hence, it is possible that most of the HIV-1 DNA, displayed in our two patients, might be mainly represented by integrated DNA fully capable of initiating HIV replication. Our data are confined to results related to proviral DNA in PBMCs, even if we must consider that viral load is also sustained by lymph node trapped CD4 T cells and other non circulating elements \[[@B6]\] that preserve replication competent virus for long periods. In the absence of therapy, a large number of HIV-1 DNA proviral copies might replicate, as assessed by the HIV-1 RNA viral load increase, leading to a relative decline of cellular DNA. In addition, we cannot exclude a further increase in DNA content in a longer follow-up.

Despite contrasting reports on the meaning of DNA proviral content in HIV-1 seropositive patients \[[@B2],[@B5],[@B9]-[@B12]\], our data obtained on closely controlled patients, emphasize the interest of studying DNA proviral content in HIV-1 infected patients. Even though it is impossible to define a proviral DNA threshold for use in clinical practice, several data showed that patients with high proviral DNA levels are more likely to experience virological failure than those with lower proviral DNA loads \[[@B11]\]. Moreover the proviral load probably reflects individual parameters because host genetic factors and response to treatment probably are involved in the constituting the pool of infected cells \[[@B30],[@B31]\]. Although RNA viral load provides important information on viral replication, HIV-1 DNA proviral load can be considered an additional marker to provide crucial information, not only during the follow-up of patients under therapy but also for individuals included in structured therapy interruptions protocols. Data obtained from our patients, who were not part of antiretroviral protocols \[[@B23]\], yield important information on the persisting timing of DNA in PBMCs.

Conclusion
==========

Only careful evaluation of virological and immunological markers is necessary to fully characterize the course of HIV-1 infection and to provide a more complete laboratory-based assessment of disease progression. However, the availability of a new standardized assay such as DNA proviral load will be important to assess the true extent of virological suppression in patients with non-quantifiable plasma viral loads and to verify the efficacy of new immune-based therapies aimed at purging HIV-1 DNA reservoirs. Although the biological meaning of DNA proviral load in PBMCs is not yet clear, several studies \[[@B2],[@B3],[@B6],[@B10]\] suggest that HIV-1 cellular DNA load may be an indicator of spread of infection whereas the plasma RNA load is indicates active infection \[[@B2]\]. However the qualitative and quantitative evaluation of both plasma HIV RNA genome and HIV-1 proviral DNA might prove crucial to understanding the course of HIV-1 infection.
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